A former Bristol graduate, and representative from GSK on our synthesis CDT board, Zoë Henley, has been shortlisted for "Rising Star Awards Shortlist 2023 in Science & Engineering". There are 233 shortlisted applicants across a range of different categories and judging will now commence to identify the five winners in each category. The winners will be announced on 22 May.
There is also an additional award called the Public Vote. All shortlisted nominees will have the opportunity to take part and call for votes from the public for this additional award. The public vote of period is open from 9 May to 16 May 2023 and votes may be cast via the website Rising Star Awards Shortlist 2023 in Science & Engineering (wearethecity-risingstars.com)
You can also vote by using the form available from this link: Rising Star Awards 2023 Voting Form (office.com)
Read Zoe Henley's bio below:
"I have a passion for the discovery of new medicines and joined GSK as an Associate Scientist in 2006, after gaining a first-class MSci Chemistry Degree from the University of Bristol.
I was promoted to a Scientific Investigator in 2013 and achieved my PhD in 2014, through a collaborative programme between GSK and the University of Strathclyde. In September 2021, I was promoted to Team Leader and now have three direct reports who I support in their professional and scientific development at GSK.
As a scientist, I have utilised my synthetic and medicinal chemistry skills to enable the identification of potential drug candidates, one of which reached Phase 2 clinical trials in patients. I have a keen interest in the application of new technologies to the drug discovery process and have led a technical network on inhaled drug design within GSK. In addition, I have developed my IT skills to become a lead user for software which assists our scientists in drug compound design and data analysis.
In 2019, I took on another role in becoming mum to my son Sam and I have since progressed my career whilst working part-time. As a chemist, I have the opportunity to make the molecule that becomes a medicine to help patients and I feel like there is no greater mission than what we do at GSK."